Core Viewpoint - The article emphasizes the urgent need for weight management due to the global obesity crisis, which is linked to various metabolic diseases and health issues. It advocates for a dual approach to weight management: self-discipline through lifestyle changes and external interventions such as medication or surgery [6][10]. Summary by Sections Obesity as a Public Health Crisis - The National Health Commission has issued a warning about the critical state of public health due to obesity, which is a major contributor to diseases like type 2 diabetes and cardiovascular issues [6]. Weight Management Approaches - Effective weight management requires both self-discipline (through exercise, diet, and sleep) and external aids (such as medications and surgical options) [6]. GLP-1 Receptor Agonists - Medications like Semaglutide and Liraglutide, which are GLP-1 receptor agonists, have been approved for weight loss. These drugs mimic the natural peptide GLP-1 in the body, aiding in appetite control and energy balance [7]. Discovery of BRINP2-Related Peptide (BRP) - A new peptide, BRP, has been identified by a Stanford University team using AI tools. This peptide shows significant potential in reducing food intake and improving blood sugar levels, comparable to GLP-1 receptor agonists, without causing anxiety or behavioral changes [8][14]. Mechanism of Action - BRP operates independently from known appetite-related peptides and activates specific neuronal pathways in the hypothalamus to regulate appetite. It enhances fat oxidation and reduces overall food intake without adverse effects [14][16]. Experimental Results - In mouse studies, BRP significantly reduced food intake and body weight, improving glucose tolerance and insulin sensitivity. The effects were similar to those of Liraglutide, indicating its potential as a weight loss treatment [14][16]. Future Directions - The discovery of BRP opens new avenues for obesity treatment, although further research is needed to understand its mechanisms and long-term safety before clinical application [18].

Core Viewpoint - The article discusses the advancements and efficacy of Tirzepatide, a dual GLP-1/GIP receptor agonist, in treating obesity and type 2 diabetes, highlighting its superior weight loss results compared to traditional GLP-1 receptor agonists like Semaglutide [7][10][12]. Group 1: Mechanism and Efficacy - GIP plays a crucial role in insulin secretion, accounting for approximately 44% of insulin release after oral glucose intake, while GLP-1 contributes only 22% [5]. - Tirzepatide, modified from GIP, has a half-life of 5 days, allowing for weekly administration, and shows better efficacy in blood sugar control and weight loss compared to GLP-1 receptor agonists [7][8]. - Clinical trials indicate that Tirzepatide significantly reduces body weight in patients with obesity or prediabetes, with weight loss percentages of 15.4% (5mg), 19.9% (10mg), and 22.9% (15mg) compared to a mere 2.1% in the placebo group [10]. Group 2: Clinical Trials and Results - The SURMOUNT-2 study demonstrated that higher doses of Tirzepatide led to an average weight loss of 15.7% (15.6kg) in type 2 diabetes patients over 72 weeks, with 81.6% of patients in the 10mg group losing over 5% of their body weight [12]. - The SURMOUNT-3 trial showed a weight reduction of up to 26.6% after 12 weeks of lifestyle intervention and 72 weeks of Tirzepatide treatment [14]. - In the SURMOUNT-5 trial, patients treated with Tirzepatide lost an average of 22.8kg, outperforming the active control group by 47% in weight loss [14]. Group 3: Safety and Side Effects - Approximately 80% of Tirzepatide users reported at least one side effect, primarily gastrointestinal issues such as nausea and diarrhea, similar to those experienced with Semaglutide [15]. - The incidence of nausea was reported at 33% for the highest dose of Tirzepatide, compared to 44% for Semaglutide, indicating a potentially lower side effect profile for Tirzepatide [15][17]. - GIP's role in appetite suppression may help mitigate some of the adverse effects associated with GLP-1 receptor activation, enhancing patient compliance and treatment efficacy [19].

Core Viewpoint - Eli Lilly's revenue growth is significantly driven by its weight loss drugs Mounjaro and Zepbound, indicating strong market performance and potential for future growth [6][7]. Financial Performance - Eli Lilly's revenue is projected to increase by 54% in Q3 2025, rising from $11.439 billion in 2024 to $17.6 billion [6]. - Mounjaro's revenue grew by 109%, from $3.112 billion to $6.515 billion, while Zepbound's revenue surged by 185%, from $1.257 billion to $3.588 billion [6]. - The company raised its annual earnings per share forecast to $23.70, up from $23.00, exceeding the initial prediction of $21.75 [6]. Market Position - Eli Lilly leads the weight loss market with its dual agonists Mounjaro and Zepbound, which target both GIP and GLP-1, compared to Novo Nordisk's single GLP-1 agonist Wegovy [7]. - Analysts express caution regarding a potential "GLP-1 bubble," highlighting risks from emerging competitors and market saturation [7]. Manufacturing Expansion - Eli Lilly plans to build a new $3 billion manufacturing facility in Katwijk, Netherlands, to enhance its production capacity for oral medications [9]. - The new plant will focus on orforglipron, an oral GLP-1 receptor agonist, with FDA approval expected by mid to late 2026 [9]. - The facility is anticipated to create 500 high-paying jobs and approximately 1,500 jobs during construction [9]. Regulatory and Strategic Initiatives - Eli Lilly is preparing for orforglipron's approval and is investing heavily in U.S. manufacturing, aligning with the trend of domestic drug production emphasized by the Trump administration [10]. - The company has not yet reached a pricing agreement with the White House, unlike competitors such as Pfizer and AstraZeneca [10]. Clinical Development - Orforglipron has shown promising results in four Phase III clinical trials, demonstrating effectiveness in blood sugar control and weight loss [11]. - The drug may represent a significant breakthrough as it does not require injections and could be priced lower than injectable alternatives [11]. - Eli Lilly plans to submit an FDA application for orforglipron by the end of 2025, potentially accelerating the approval process through the National Priority Voucher program [11].

Core Viewpoint - The article highlights the significant association between the consumption of food emulsifiers and the increased risk of type 2 diabetes, emphasizing the need for stricter health risk monitoring of food additives [7][12]. Group 1: Research Findings - A recent study published in *The Lancet Diabetes & Endocrinology* reveals a dose-dependent relationship between commonly used emulsifiers and the incidence of type 2 diabetes, based on a cohort of over 100,000 participants [7][11]. - The study identified seven common emulsifiers, including carboxymethyl cellulose and potassium phosphate, that are significantly correlated with diabetes incidence [11]. - The research indicates that 99.7% of participants consumed at least one emulsifier, with the highest intake from ultra-processed fruit and vegetable products (18.5%), baked goods (14.7%), and dairy products (10.0%) [11]. Group 2: Methodology - The study utilized a comprehensive data collection approach, requiring participants to complete multiple 24-hour dietary recalls over time to minimize seasonal bias [9][10]. - A total of 61 emulsifiers were identified and assessed for individual cumulative exposure using innovative evaluation methods [10]. - The research employed advanced statistical models to accurately quantify the relationship between emulsifier exposure and diabetes risk, ensuring robust findings [10]. Group 3: Implications for Public Health - The findings underscore the urgent need for further epidemiological studies, ethical short-term intervention trials, and preclinical experiments to establish a more complete evidence base regarding food additives [12]. - If validated, these results could prompt a reevaluation of current food additive regulations globally, leading to safer food industry practices and improved public health outcomes [12].

Core Insights - Obesity has become a global health crisis affecting over one billion people, with abnormal growth of adipose tissue being a core risk factor for various diseases including type 2 diabetes and cardiovascular diseases [7] - A groundbreaking study published in Nature on July 9, 2025, by a UK research team revealed key cellular types and molecular events involved in the remodeling of human adipose tissue during obesity and weight loss [7][10] - The study identified a selective aging susceptibility in metabolic, precursor, and vascular cells, confirming that weight loss can effectively reverse this aging process [7][10] Group 1: Study Findings - The research constructed a high-precision spatial single-nucleus transcriptome map covering 171,247 cells from 70 subjects, providing insights into the cellular composition and functional dynamics during weight gain and loss [8][10] - In obese states, there is significant immune cell infiltration in adipose tissue, primarily by macrophages, while the number of mature adipocytes decreases, indicating increased cell death or impaired renewal functions [8][12] - Weight loss interventions can significantly reverse these pathological changes, enhancing metabolic health [12] Group 2: Molecular Mechanisms - Weight loss leads to a significant downregulation of p21 expression and activation of cell cycle progression genes, demonstrating its anti-aging effects [10] - The study identified six functional groups of transcription factors involved in the aging process, which may exacerbate the cycle of stress, aging, and tissue damage [10][12] - Weight loss treatment can effectively shut down this transcriptional cascade, contributing to improved metabolic health [12] Group 3: Implications for Treatment - The findings provide breakthrough insights into the mechanisms of adipose tissue dysfunction and the reversal effects of weight loss, laying a solid foundation for future therapeutic developments [12]

Core Insights - The article highlights the significant benefits of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), emphasizing its ability to improve walking ability and quality of life without being affected by individual patient characteristics [8][19][20]. Group 1: Research Findings - Semaglutide shows a notable improvement in maximum walking distance (MWD) and pain-free walking distance (PFWD) for patients with symptomatic PAD, regardless of diabetes duration, BMI, or blood sugar control [10][12][13][14]. - The STRIDE trial included 792 patients with symptomatic PAD, demonstrating that all patient subgroups benefited from Semaglutide treatment [9][10]. - The study revealed that the improvement in walking ability was independent of weight loss and blood sugar control, suggesting a novel mechanism of action for Semaglutide [17][18]. Group 2: Clinical Implications - The findings indicate that Semaglutide can serve as a comprehensive treatment option for PAD in type 2 diabetes patients, enhancing lower limb blood circulation and functional capacity [20][21]. - The safety profile of Semaglutide was comparable to that of the placebo group, with no significant increase in adverse events, including hypoglycemia [18][19]. - This research opens new avenues for treating the challenging combination of diabetes and PAD, providing valuable clinical guidance [21].

整理 | GLP1减重宝典内容团队 此次裁员是杜斯达尔上月启动的公司重组计划的一部分。 根据诺和诺德首席执行官迈克·杜斯达尔（Mike Doustdar）周五在领英发布的帖子，诺和诺德已经基本完成了面向9000名员工的裁员通知工 作。他补充道，虽然此次裁员计划是全球范围内实施的，但由于不同地区的法律规定差异，员工通知的进度有所不同。 目前，诺和诺德在全球最大药品市场——美国，正面临来自礼来制药的激烈竞争。尤其是在减肥药品市场，规模已达到1500亿美元，并且正在 蓬勃发展，诺和诺德也在寻求进一步突破。 这家丹麦制药巨头正与另一主要竞争对手辉瑞，围绕梅塞拉（Metsera）旗下的试验性肥胖症疗法展开激烈竞购。两家公司都希望获得该公司一 款每月注射一次的胰高血糖素样肽-1（GLP-1）类注射药物的相关权益。 目前，市场上热销的注射类减肥药物，如诺和诺德的Wegovy和礼来制药的Zepbound，均为每周注射一次的剂型。而梅塞拉则是多家专注于研 发试验性减肥药物的公司之一。 *本文仅供医疗卫生专业人士参考 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝 ...

Core Viewpoint - GLP-1 agonists, such as semaglutide and tirzepatide, are popular weight loss medications, but a significant number of users discontinue their use within a year due to various factors, including cost, side effects, and prescription limitations [5][7]. Group 1: Impact of Discontinuation - A study indicated that approximately two-thirds of individuals who started using GLP-1 agonists in the U.S. stopped within a year [5]. - Upon discontinuation, many individuals experience weight regain, with studies showing that those who switched to a placebo regained nearly 7% of their weight after 11 months [12]. - An observational study found that 44% of individuals who stopped semaglutide regained at least 25% of their weight within a year [12]. Group 2: Health Risks Associated with Weight Regain - Discontinuation of semaglutide not only leads to weight regain but also a resurgence of health risks, including increased blood pressure, blood sugar, and cholesterol levels [13]. - Abdominal fat, which is linked to metabolic issues like heart disease and insulin resistance, tends to rebound after stopping the medication [13]. Group 3: Recommendations for Discontinuation - Gradual tapering off the medication rather than abrupt cessation may help mitigate rebound hunger and weight gain [14]. - Continuous monitoring of appetite and weight is advised for those who choose to stop the medication [14]. - Lifestyle changes, including diet and exercise, should be maintained even after discontinuation to help manage weight [15]. Group 4: Optimal Dosing Strategies - Research presented at the European Obesity Congress indicated that starting patients on the lowest effective dose of semaglutide and only increasing it when necessary can lead to significant weight loss while minimizing side effects [17]. - In a study, participants lost an average of 14.9 kg over 76 weeks while maintaining a low dose of semaglutide [17]. Group 5: Efficacy of Lower Doses - Another study demonstrated that a weekly dose of 0.5 mg of semaglutide resulted in an approximate 11% weight loss among participants [19].

Core Viewpoint - The article discusses the collaboration between Hong Kong-listed company Four Seasons Pharmaceutical (00460.HK) and U.S. biotechnology firm Abalone Bio to develop a new generation of obesity treatment drugs, highlighting the intensifying competition in the global weight loss drug market [4][5]. Group 1: Collaboration Details - Four Seasons Pharmaceutical will gain access to Abalone Bio's proprietary "cell receptor bias technology platform," which aims to enhance weight loss efficacy while reducing gastrointestinal side effects [5]. - The partnership plans to complete candidate drug screening by 2026 and will share global commercialization rights [5]. - Abalone Bio was founded by scholars from Stanford University, and its core technology has attracted interest from major pharmaceutical companies like Novartis and Eli Lilly [5]. Group 2: Industry Context - The collaboration signifies a strategic move by Chinese pharmaceutical companies in the ongoing GLP-1 weight loss drug development trend, indicating a competitive landscape in the global weight loss drug market [4][5]. - The article emphasizes the importance of this partnership in addressing Four Seasons Pharmaceutical's shortcomings in target optimization, providing technical support for future regulatory submissions in both the U.S. and China [5].

Core Insights - The article discusses the potential of multi-receptor agonists, specifically LY3437943, in improving health outcomes for patients with type 2 diabetes and obesity, showing promising results in both short-term and long-term health improvements [5][10]. Group 1: Study Overview - A randomized, double-blind, placebo-controlled phase 1b trial was conducted from December 2019 to December 2020 across four research centers in the U.S., involving 72 adult patients with type 2 diabetes [6]. - Patients were randomly assigned to receive different doses of LY3437943, a placebo, or a control group receiving 1.5 mg of Dulaglutide, with treatment lasting 12 weeks [6]. Group 2: Safety and Efficacy Results - The primary focus was on the safety and tolerability of LY3437943, while secondary endpoints assessed pharmacodynamics and pharmacokinetics [7]. - Adverse events related to treatment were reported in 63% of the LY3437943 group, 60% in the Dulaglutide group, and 54% in the placebo group, with gastrointestinal symptoms being the most common adverse reactions [7]. Group 3: Pharmacokinetics and Outcomes - Pharmacokinetic analysis indicated a proportional relationship between LY3437943's pharmacological parameters and dosage, with a half-life of approximately 6 days [8]. - After 12 weeks, average daily blood glucose levels significantly decreased in the high-dose groups compared to baseline, with reductions of 2.8 mmol/L, 3.1 mmol/L, and 2.9 mmol/L for the respective high-dose groups [8]. - Hemoglobin A1c levels also improved significantly in the high-dose groups, with reductions of 1.4%, 1.6%, and 1.2% [10]. - Weight loss was dose-dependent, with the highest dose group achieving an average weight reduction of 8.96 kg [10]. Group 4: Conclusion and Future Research - Overall, LY3437943 demonstrated safety profiles comparable to existing incretin-based therapies while significantly improving blood glucose control and weight status over the 12-week treatment period [10]. - These findings lay a solid foundation for further phase 2 clinical studies in the treatment of type 2 diabetes and obesity [10].